PerkinElmer Announces Collaboration with China's National Center for Drug Screening
A personalized drug research and development platform will validate biomarkers for individualized disease treatment for Chinese patients.
PerkinElmer will collaborate with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China, the company announced in a press release. The two organizations will share knowledge, expertise, and innovative capabilities to establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients.
The program will include sequencing patient samples in order to establish genomic information for drug profiling, including validation of biomarkers for personalized disease treatment and related informatics solutions. As a part of this program, PerkinElmer and NCDS will first undertake a study on metabolic diseases to validate new diagnostics for the Chinese populations through utilizing next-generation sequencing technologies. Once optimized, the technology platform will be implemented in testing laboratories and hospitals throughout China.
NCDS is a joint program of China’s Ministry of Science and Technology, the Chinese Academy of Sciences, and the Shanghai municipality government. At present, it is the only national center specializing in screening for new drugs. As a public technology platform, the Center offers drug-screening services and technical consultation to universities, research institutions, and pharmaceutical companies in China.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
